INTRODUCTION RESULTS
• Ledipasvir/Sofosbuvir (LDV/SOF) single tablet regimen (STR) is approved in Europe for chronic hepatitis C (CHC) patients with genotypes (GT) 1, 3 and 4.
• In the ION-3 study 8 weeks (8w) of LDV/SOF was noninferior to 12w in previously untreated GT1 patients without cirrhosis with no benefit for the addition of ribavirin (RBV).
• According to the European Medicines Agency (EMA) label 1 8w may be considered in treatment naïve, noncirrhotic patients.
• 8w LDV/SOF is predominantly prescribed according to the EMA label 1 for treatment-naïve non-cirrhotic CHC patients, with the addition of HCV RNA <6 million IU/mL at baseline. The preliminary results of this real world study indicate that in line with clinical trials, an 8-week regimen of LDV/SOF, is a highly effective and well tolerated if used in patients according to the EMA label.
• The aim of the present analysis is to characterise the population receiving 8w LDV/SOF and to describe outcomes in clinical practice.
• CHC patients treated with 8w LDV/SOF in a single centre (with SVR results after 12 weeks of follow-up (SVR12) available at end of October 2015) were included in this analysis.
• Baseline characteristics, prior treatment history, safety and effectiveness were investigated.
• HCV RNA was qualitatively measured by Roche COBAS® AmpliPrep/COBAS® TaqMan® with a cut-off of <12 IU/ml. Fibrosis was measured by FibroScan® with cut-off values for METAVIR stage F3 or less of ≤12.3kPa.
• The analysis was performed using descriptive statistics.
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Results
• 103 patients met the inclusion criteria and initiated 8w treatment with LDV/SOF between 21/11/2014 to 01/06/2015
• No patients had ribavirin (R) added to the STR
• 97.1% of patients were treatment naïve; 1 patient had previously relapsed to pegIFN + RBV therapy and two patients had a null response to IFN monotherapy
• All patients were non-cirrhotic; two patients had HCV RNA > 6 million IU/mL (7,079,457 and 13,803,842; Metavir stages F2 and F0 respectively)
• 91.5% of patients reported at least one co-morbidity; depression was reported in 16% of those patients Table 1 . Baseline characteristics
• In patients with available outcome data, the full response at 4 weeks of treatment was 100% (n=101/101).
• In patients with available outcome data, the SVR4 was 100% (n=94/94) and SVR12 was 100% (n=103/103).
• In patients with HIV co-infection and available outcome data, the SVR4 was 100% (n=3/3) and SVR12 was 100% (n=3/3).
• 1.9% (n=2) experienced grade 3 or 4 adverse events (AE)
• 1.0% (n=1) experienced AE possibly related to LDV/SOF
• No AE lead to treatment discontinuation or death
Adverse events Total cohort (n=103) Any AEs (Grades 3 & 4), n 2
Headache, n 1
Flu, n 1
AEs 'probably' related to treatment, n 0
AEs 'possibly' related to treatment, n 1
AEs 'probably' related to SOF, n 1
Cephalgia, n 1
AEs 'possibly' related to SOF, n 0
AEs leading to discontinuation, n 0 • Evidence of non-adherence, assessed upon the discretion of the investigators and based on patient adherence to schedules / appointments, patient statements and congruence to the prescriptions was reported in 3.9 % of patients.
